Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Hong Kong stocks are rising rapidly; who are the Block Orders driving this round of increase?

According to EPFR data, as of this Wednesday (February 12), active foreign capital continues to Outflow from China market, and even slightly accelerated.

CICC strategyFeb 17 08:39

DeepSeek has sparked an unprecedented wave of AI applications! The market increasingly believes in the 'bull market narrative' of Software stocks.

With the significant decrease in AI training costs led by DeepSeek, as well as the sharp drop in token costs on the inference side, AI agents and generative AI Software are expected to accelerate their penetration into various industries.

Zhitong FinanceFeb 14 23:34

Despite the bullish predictions from Wall Street, China International Capital Corporation disclosed that foreign capital has been flowing out of Hong Kong stocks after the holiday, with a slowdown in inflow and selling of Xiaomi and Semiconductor Manufact

Active foreign investment continues to experience Outflow, while Inflow from the south is narrowing.

wallstreetcnFeb 9 10:55

Product quantity and price have both declined, coupled with impairments in goodwill and intangible Assets. Guangxi Wuzhou Zhongheng Group expects a loss of 0.2 billion to -0.4 billion yuan in 2024 | Interpretations.

① Guangxi Wuzhou Zhongheng Group released its annual performance forecast for 2024, expecting a net loss of 0.22 billion yuan to -0.43 billion yuan, with the non-recurring net income also expecting a loss of 0.2 billion yuan to -0.4 billion yuan. ② Despite the performance pressure, Guangxi Wuzhou Zhongheng Group simultaneously announced multiple measures to maintain the company's stock price, including stock cancellations, share repurchases, and voluntary locks by major shareholders.

cls.cnJan 24 23:11

The net profit of two A-share mid-range liquor companies is expected to decline by more than 70% last year, with the decrease in performance exceeding the expectations of brokerages.| Interpretations

1. Shede Spirits and Jiugui Liquor are expected to see a decline in net income attributable to the parent company of 70% and 90% respectively in 2024, with the decline in performance exceeding most Brokerage predictions. 2. The Baijiu Industry is undergoing a deep adjustment period, where squeezed competition intensifies and sales of Baijiu products come under pressure, especially in the consumption demand for mid-to-low end products. 3. Goldman Sachs predicts that Shede Spirits' target for 2025 may be to achieve balanced growth in volume and price, with the first half of the year remaining under pressure while the second half may gradually recover.

cls.cnJan 23 22:48